Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 12, 2021 03:00 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19

Second monoclonal antibody from Vir-GSK collaboration to be investigated as a potential COVID-19 treatmentPreclinical data suggest VIR-7832 has two distinguishing properties: enhanced ability to clear...
January 06, 2021 08:00 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology Announces Initiation of Phase 1 Clinical Trial to Evaluate a Novel Vaccine Platform

SAN FRANCISCO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, announced...
January 05, 2021 08:00 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology to Present at 39th Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today...
December 17, 2020 16:01 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19

– Randomized, placebo-controlled, multicenter, global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalized adults with COVID-19 – SAN FRANCISCO and LONDON, Dec. 17,...
December 10, 2020 08:00 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology Appoints Jeffrey Hatfield to its Board of Directors

SAN FRANCISCO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Jeffrey Hatfield, an accomplished industry executive with more than three...
November 10, 2020 16:01 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2020 Financial Results

SAN FRANCISCO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today...
November 06, 2020 08:00 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology Publishes New Research Characterizing Variation in the SARS-CoV-2 Spike Protein and Virulence of a Prevalent Immune Evasion Variant, N439K

SAN FRANCISCO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the publication of new research demonstrating that the immunodominant SARS-CoV-2 receptor...
October 27, 2020 16:01 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2020 Financial Results on November 10, 2020

SAN FRANCISCO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today...
October 21, 2020 08:00 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology Presents New Data on VIR-2482, the Company’s Investigational Monoclonal Antibody for the Prevention of Influenza A, at IDWeek 2020

– Preclinical data show VIR-2482 has broad neutralizing potential against all major strains of influenza A from the last 100 years – – Extended half-life observed in Phase 1 demonstrates potential...
October 13, 2020 16:01 ET | Source: Vir Biotechnology, Inc.

Vir and Alnylam to Webcast Virtual Fireside Chat at H.C. Wainwright Hepatitis B Virus Mini-Conference

SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that Phil Pang, M.D.,...